Matthew B Young1, Seth D Norrholm1,2, Lara M Khoury3, Tanja Jovanovic1,2, Sheila A M Rauch1,2, Collin M Reiff1, Boadie W Dunlop1, Barbara O Rothbaum1, Leonard L Howell4. 1. Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, 954 Gatewood Rd NE #2101, Atlanta, GA, 30329, USA. 2. Atlanta VA Medical Center, Mental Health Service Line, Decatur, GA, USA. 3. Emory University, Atlanta, GA, USA. 4. Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, 954 Gatewood Rd NE #2101, Atlanta, GA, 30329, USA. lhowell@emory.edu.
Abstract
RATIONALE: 3,4-Methylenedioxymethamphetamine (MDMA) persistently improves symptoms of post-traumatic stress disorder (PTSD) when combined with psychotherapy. Studies in rodents suggest that these effects can be attributed to enhancement of fear memory extinction. Therefore, MDMA may improve the effects of exposure-based therapy for PTSD, particularly in treatment-resistant patients. However, given MDMA's broad pharmacological profile, further investigation is warranted before moving to a complex clinical population. OBJECTIVES: We aimed to inform clinical research by providing a translational model of MDMA's effect, and elucidating monoaminergic mechanisms through which MDMA enhances fear extinction. METHODS: We explored the importance of monoamine transporters targeted by MDMA to fear memory extinction, as measured by reductions in conditioned freezing and fear-potentiated startle (FPS) in mice. Mice were treated with selective inhibitors of individual monoamine transporters prior to combined MDMA treatment and fear extinction training. RESULTS: MDMA enhanced the lasting extinction of FPS. Acute and chronic treatment with a 5-HT transporter (5-HTT) inhibitor blocked MDMA's effect on fear memory extinction. Acute inhibition of dopamine (DA) and norepinephrine (NE) transporters had no effect. 5-HT release alone did not enhance extinction. Blockade of MDMA's effect by 5-HTT inhibition also downregulated 5-HT2A-mediated behavior, and 5-HT2A antagonism disrupted MDMA's effect on extinction. CONCLUSIONS: We validate enhancement of fear memory extinction by MDMA in a translational behavioral model, and reveal the importance of 5-HTT and 5-HT2A receptors to this effect. These observations support future clinical research of MDMA as an adjunct to exposure therapy, and provide important pharmacological considerations for clinical use in a population frequently treated with 5-HTT inhibitors.
RATIONALE: 3,4-Methylenedioxymethamphetamine (MDMA) persistently improves symptoms of post-traumatic stress disorder (PTSD) when combined with psychotherapy. Studies in rodents suggest that these effects can be attributed to enhancement of fear memory extinction. Therefore, MDMA may improve the effects of exposure-based therapy for PTSD, particularly in treatment-resistant patients. However, given MDMA's broad pharmacological profile, further investigation is warranted before moving to a complex clinical population. OBJECTIVES: We aimed to inform clinical research by providing a translational model of MDMA's effect, and elucidating monoaminergic mechanisms through which MDMA enhances fear extinction. METHODS: We explored the importance of monoamine transporters targeted by MDMA to fear memory extinction, as measured by reductions in conditioned freezing and fear-potentiated startle (FPS) in mice. Mice were treated with selective inhibitors of individual monoamine transporters prior to combined MDMA treatment and fear extinction training. RESULTS:MDMA enhanced the lasting extinction of FPS. Acute and chronic treatment with a 5-HT transporter (5-HTT) inhibitor blocked MDMA's effect on fear memory extinction. Acute inhibition of dopamine (DA) and norepinephrine (NE) transporters had no effect. 5-HT release alone did not enhance extinction. Blockade of MDMA's effect by 5-HTT inhibition also downregulated 5-HT2A-mediated behavior, and 5-HT2A antagonism disrupted MDMA's effect on extinction. CONCLUSIONS: We validate enhancement of fear memory extinction by MDMA in a translational behavioral model, and reveal the importance of 5-HTT and 5-HT2A receptors to this effect. These observations support future clinical research of MDMA as an adjunct to exposure therapy, and provide important pharmacological considerations for clinical use in a population frequently treated with 5-HTT inhibitors.
Entities:
Keywords:
Fear extinction; Fear-potentiated startle; MDMA; Monoamines; Serotonin
Authors: Eileen K Sawyer; Jiyoung Mun; Jonathon A Nye; Heather L Kimmel; Ronald J Voll; Jeffrey S Stehouwer; Kenner C Rice; Mark M Goodman; Leonard L Howell Journal: Neuropsychopharmacology Date: 2012-03-21 Impact factor: 7.853
Authors: T Daldrup; J Remmes; J Lesting; S Gaburro; M Fendt; P Meuth; V Kloke; H-C Pape; T Seidenbecher Journal: Genes Brain Behav Date: 2015-03-25 Impact factor: 3.449
Authors: Michael C Mithoefer; Mark T Wagner; Ann T Mithoefer; Lisa Jerome; Rick Doblin Journal: J Psychopharmacol Date: 2010-07-19 Impact factor: 4.153
Authors: Cédric M Hysek; Linda D Simmler; Valentina G Nicola; Nerina Vischer; Massimiliano Donzelli; Stephan Krähenbühl; Eric Grouzmann; Jörg Huwyler; Marius C Hoener; Matthias E Liechti Journal: PLoS One Date: 2012-05-04 Impact factor: 3.240
Authors: Daniel W Curry; Matthew B Young; Andrew N Tran; Georges E Daoud; Leonard L Howell Journal: Neuropharmacology Date: 2017-10-06 Impact factor: 5.250
Authors: Carine Bécamel; Dimitri De Bundel; Błażej D Pędzich; Sarah Rubens; Mehdi Sekssaoui; Anouk Pierre; Andries Van Schuerbeek; Philippe Marin; Joel Bockaert; Emmanuel Valjent Journal: Neuropsychopharmacology Date: 2022-04-21 Impact factor: 8.294
Authors: Elizabeth G Pitts; Daniel W Curry; Karly N Hampshire; Matthew B Young; Leonard L Howell Journal: Psychopharmacology (Berl) Date: 2017-12-16 Impact factor: 4.530
Authors: Laís F Berro; Hannah Shields; Melis Odabas-Geldiay; Barbara O Rothbaum; Monica L Andersen; Leonard L Howell Journal: Exp Clin Psychopharmacol Date: 2018-06-25 Impact factor: 3.157